What is it used for?
LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test .LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test .
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- lazertiniblazertinib
- Form and strength
- TABLET, FILM COATED · 240 mg; TABLET, FILM COATED · 80 mgTABLET, FILM COATED · 240 mg; TABLET, FILM COATED · 80 mg
- Manufacturer / applicant
- JANSSEN BIOTECH, INC.JANSSEN BIOTECH, INC.
Tablets 80 mg tablets: yellow, oval film-coated tablet, debossed with "LZ" on one side and "80" on the other side. Each tablet contains 80 mg of lazertinib. 240 mg tablets: reddish purple, oval film-coated tablet, debossed with "LZ" …Tablets 80 mg tablets: yellow, oval film-coated tablet, debossed with "LZ" on one side and "80" on the other side. Each tablet contains 80 mg of lazertinib. 240 mg tablets: reddish purple, oval film-coated tablet, debossed with "LZ" …
Safety and clinical review
- Venous Thromboembolic EventsVenous Thromboembolic Events
- Interstitial Lung Disease (ILD)/PneumonitisInterstitial Lung Disease (ILD)/Pneumonitis
- Dermatologic Adverse ReactionsDermatologic Adverse Reactions
- HepatotoxicityHepatotoxicity
- Ocular ToxicityOcular Toxicity
- Embryo-Fetal ToxicityEmbryo-Fetal Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Lazcluze used for?
LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test .LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test .
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Lazcluze should I ask about?
TABLET, FILM COATED · 240 mg; TABLET, FILM COATED · 80 mgTABLET, FILM COATED · 240 mg; TABLET, FILM COATED · 80 mg
Read the primary sourceWhat determines the price of Lazcluze?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Lazcluze?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.